Artificial intelligence is increasingly shaping pharmaceutical research, and VERAXA Biotech (NASDAQ: VRXA) is positioning itself to benefit through a new collaboration with AI-focused partner Ardigen. The partnership aims to strengthen development of VERAXA's BiTAC(R) oncology platform by using AI-enabled target discovery and validation, according to a press release.
VERAXA, an emerging leader in designing novel cancer therapies, announced the collaboration to identify optimal dual-target combinations for T-cell engagers and antibody-drug conjugates. The company's Boolean “AND-gated” BiTAC(R) technology presents a use case that may be particularly well suited for AI-assisted target selection and therapeutic design, the release noted.
The agreement brings together VERAXA's antibody engineering capabilities with Ardigen's expertise in artificial intelligence, computational biology and bioinformatics. Ardigen, headquartered in Kraków, Poland, with U.S. operations in San Francisco, has supported more than 700 discovery projects. The collaboration aims to reduce development risks while improving research productivity, leveraging AI analysis of historical clinical and preclinical datasets to help identify promising targets that were previously abandoned because of safety concerns.
This partnership reflects a broader trend in the pharmaceutical industry, where major companies are expanding AI collaborations across oncology and immunology. By integrating AI into drug discovery, firms can analyze complex biological data more efficiently, identify drug targets faster, and improve clinical development decisions. For VERAXA, the collaboration could accelerate the development of its BiTAC platform, which is designed to create more targeted cancer therapies with potentially fewer side effects.
The implications for the industry are significant. AI-assisted target selection could reduce the high failure rate in drug development, particularly in oncology, where many promising candidates fail due to safety issues or lack of efficacy. By using machine learning to analyze historical data, VERAXA and Ardigen aim to salvage previously abandoned targets and bring new therapies to patients more quickly.
For investors, the announcement highlights VERAXA's commitment to leveraging cutting-edge technology to enhance its pipeline. The company's stock, traded on NASDAQ under VRXA, may benefit from the growing interest in AI-driven drug discovery. However, as with all forward-looking statements, risks remain, including those outlined in VERAXA's SEC filings.
Readers can find more details about the collaboration and VERAXA's newsroom at https://ibn.fm/VRXA. The full terms of use and disclaimers are available at http://IBN.fm/Disclaimer.
